肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

研究性药物Alvocidib联合阿糖胞苷/柔红霉素治疗初治AML患者疗效明显

2019-06-16 Allan MedSci原创

Alvocidib阿糖胞苷/柔红霉素AML
关注

Tolero是一家致力于开发血液肿瘤​疗法的医药公司，近日在第24届欧洲血液学协会（EHA）大会上公布了I期Zella 101研究的初步结果，该研究评估了强效CDK9抑制剂alvocidib联合阿糖胞苷/柔红霉素治疗初治急性髓性白血病（AML）患者的安全性和临床活性。

Tolero是一家致力于开发血液肿瘤​疗法的医药公司，近日在第24届欧洲血液学协会（EHA）大会上公布了I期Zella 101研究的初步结果，该研究评估了强效CDK9抑制剂alvocidib联合阿糖胞苷/柔红霉素治疗初治急性髓性白血病（AML）患者的安全性和临床活性。该研究的初步数据表明，联合疗法具有可接受的安全性和临床活性。在18名可评估的患者中，超过四分之三（78％，n = 14）达到完全缓解（CR）或血液恢复不完全的完全缓解（CRi）。

急性髓性白血病（AML）是一种由骨髓、外周血或髓外组织中髓样原始细胞克隆性扩增导致的疾病。至少存在 20% 的骨髓原始细胞即可确诊。


原始出处：

http://www.firstwordpharma.com/node/1647681#axzz5r0RYRQBl

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987629, encodeId=47e6198e62934, content=<a href='/topic/show?id=88552385d8' target=_blank style='color:#2F92EE;'>#Alvocidib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2385, encryptionId=88552385d8, topicName=Alvocidib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Apr 09 18:15:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991611, encodeId=eb94199161160, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Dec 20 03:15:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749221, encodeId=a4601e4922134, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Sat Feb 29 07:15:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367878, encodeId=61d036e878f6, content=靶向药物越来越多啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 17 06:56:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032196, encodeId=5492103219624, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 16 22:15:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367856, encodeId=750036e856dc, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jun 16 20:10:26 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2020-04-09 qidongfanjian

    #Alvocidib#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1987629, encodeId=47e6198e62934, content=<a href='/topic/show?id=88552385d8' target=_blank style='color:#2F92EE;'>#Alvocidib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2385, encryptionId=88552385d8, topicName=Alvocidib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Apr 09 18:15:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991611, encodeId=eb94199161160, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Dec 20 03:15:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749221, encodeId=a4601e4922134, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Sat Feb 29 07:15:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367878, encodeId=61d036e878f6, content=靶向药物越来越多啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 17 06:56:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032196, encodeId=5492103219624, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 16 22:15:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367856, encodeId=750036e856dc, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jun 16 20:10:26 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-12-20 xlxchina

    #CID#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1987629, encodeId=47e6198e62934, content=<a href='/topic/show?id=88552385d8' target=_blank style='color:#2F92EE;'>#Alvocidib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2385, encryptionId=88552385d8, topicName=Alvocidib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Apr 09 18:15:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991611, encodeId=eb94199161160, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Dec 20 03:15:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749221, encodeId=a4601e4922134, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Sat Feb 29 07:15:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367878, encodeId=61d036e878f6, content=靶向药物越来越多啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 17 06:56:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032196, encodeId=5492103219624, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 16 22:15:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367856, encodeId=750036e856dc, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jun 16 20:10:26 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2020-02-29 wolongzxh

    #红霉素#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1987629, encodeId=47e6198e62934, content=<a href='/topic/show?id=88552385d8' target=_blank style='color:#2F92EE;'>#Alvocidib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2385, encryptionId=88552385d8, topicName=Alvocidib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Apr 09 18:15:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991611, encodeId=eb94199161160, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Dec 20 03:15:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749221, encodeId=a4601e4922134, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Sat Feb 29 07:15:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367878, encodeId=61d036e878f6, content=靶向药物越来越多啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 17 06:56:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032196, encodeId=5492103219624, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 16 22:15:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367856, encodeId=750036e856dc, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jun 16 20:10:26 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-17 cqykthl

    靶向药物越来越多啦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1987629, encodeId=47e6198e62934, content=<a href='/topic/show?id=88552385d8' target=_blank style='color:#2F92EE;'>#Alvocidib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2385, encryptionId=88552385d8, topicName=Alvocidib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Apr 09 18:15:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991611, encodeId=eb94199161160, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Dec 20 03:15:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749221, encodeId=a4601e4922134, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Sat Feb 29 07:15:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367878, encodeId=61d036e878f6, content=靶向药物越来越多啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 17 06:56:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032196, encodeId=5492103219624, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 16 22:15:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367856, encodeId=750036e856dc, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jun 16 20:10:26 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-16 内科新手

    谢谢梅斯提供这么好的信息，学到很多

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1987629, encodeId=47e6198e62934, content=<a href='/topic/show?id=88552385d8' target=_blank style='color:#2F92EE;'>#Alvocidib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2385, encryptionId=88552385d8, topicName=Alvocidib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Apr 09 18:15:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991611, encodeId=eb94199161160, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Dec 20 03:15:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749221, encodeId=a4601e4922134, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Sat Feb 29 07:15:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367878, encodeId=61d036e878f6, content=靶向药物越来越多啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 17 06:56:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032196, encodeId=5492103219624, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 16 22:15:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367856, encodeId=750036e856dc, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jun 16 20:10:26 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-16 1209e435m98(暂无昵称)

    学习了，谢谢分享

    0